Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

1(33.3%)

N/A

1(33.3%)

Phase 1

1(33.3%)

3Total

Phase 4(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03090919Not ApplicableWithdrawn

The INFUSE Trial - Intervening With Platelet Transfusions in Sepsis

Role: lead

NCT02952638Terminated

Dietary Sources of Lysophospholipids

Role: lead

NCT02506985Phase 4Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Role: lead

NCT01241903Phase 1Completed

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Role: lead

All 4 trials loaded